Farzaneh Montazerifar - Pregnancy Health Research Center, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Mansour Karajibani - Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Gohar Sedaghat - Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Shadi Shourestani - Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Fatemeh Azar Nour - Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Ahmad Bolouri - Department of Cardiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

Background: Diabetes and obesity are associated with an increased risk of cardiovascular disease. Irisin is a newly recognized peptidic myokine with anti-obesity and anti-diabetic properties. This study aims to investigate the relationship between serum irisin levels with cardiometabolic biomarkers in patients with type ۲ diabetes mellitus (T۲DM). Methods: In this comparative cross- sectional study, ۸۰ T۲DM patients and ۸۰ control participants (adjusted by age, body mass index (BMI), and physical activity) referring to Bou Ali Hospital in Zahedan, Iran, were enrolled. Serum irisin concentrations, anthropometric, and biochemical parameters were assessed. Results: Serum irisin level was significantly lower in T۲DM patients compared to control group. Multiple linear regression analysis revealed that after adjustment for age, irisin was negatively associated with waist circumference (WC, P < ۰.۰۱) and waist to height ratio (WHtR, P < ۰.۰۱), homeostasis model assessment insulin resistance (HOMA-IR, P = ۰.۰۰۹), triglycerides (TG, P = ۰.۰۱۶), and positively associated with high density lipoprotein cholesterol (HDL-c, P = ۰.۰۳) in diabetic patients. Conclusion: The findings suggest that irisin can be used as a marker for predicting of obesity-related cardiometabolic biomarkers, insulin resistance, and incident T۲DM.

Irisin, Insulin Rrsistance, Obesity, Cardiometabolic Risk factors, Type ۲ diabetes mellitus